References
- Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9. https://doi.org/10.1016/S0140-6736(12)60988-X
- Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84. https://doi.org/10.1056/NEJMoa0808991
- Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322-9. https://doi.org/10.1136/thoraxjnl-2012-202698
- Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98. https://doi.org/10.1056/NEJMoa1104623
- Sutherland ER, King TS, Icitovic N, Ameredes BT, Bleecker E, Boushey HA, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010;126:747-53. https://doi.org/10.1016/j.jaci.2010.07.024
- Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012;367:1198-207. https://doi.org/10.1056/NEJMoa1208606
- Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA 2012;308:987-97. https://doi.org/10.1001/2012.jama.10893
- Brozek JL, Kraft M, Krishnan JA, Cloutier MM, Lazarus SC, Li JT, et al. Long-acting beta2-agonist step-off in patients with controlled asthma. Arch Intern Med 2012;172:1365-75. https://doi.org/10.1001/archinternmed.2012.3250
- Wells KE, Peterson EL, Ahmedani BK, Severson RK, Gleason- Comstock J, Williams LK. The relationship between combination inhaled corticosteroid and long-acting beta-agonist use and severe asthma exacerbations in a diverse population. J Allergy Clin Immunol 2012;129:1274-9.e2. https://doi.org/10.1016/j.jaci.2011.12.974
- Sumino K, Sugar EA, Irvin CG, Kaminsky DA, Shade D, Wei CY, et al. Methacholine challenge test: diagnostic characteristics in asthmatic patients receiving controller medications. J Allergy Clin Immunol 2012;130:69-75.e6. https://doi.org/10.1016/j.jaci.2012.02.025
- Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647-54.e10. https://doi.org/10.1016/j.jaci.2012.06.025
- Greenberg S, Liu N, Kaur A, Lakshminarayanan M, Zhou Y, Nelsen L, et al. The asthma disease activity score: a discriminating, responsive measure predicts future asthma attacks. J Allergy Clin Immunol 2012;130:1071-7.e10. https://doi.org/10.1016/j.jaci.2012.07.057
- Eisner MD, Yegin A, Trzaskoma B. Severity of asthma score predicts clinical outcomes in patients with moderate to severe persistent asthma. Chest 2012;141:58-65. https://doi.org/10.1378/chest.11-0020
- Schatz M, Zeiger RS, Yang SJ, Chen W, Crawford W, Sajjan S, et al. The relationship of asthma impairment determined by psychometric tools to future asthma exacerbations. Chest 2012;141:66-72. https://doi.org/10.1378/chest.11-0574
- Hawkins GA, Robinson MB, Hastie AT, Li X, Li H, Moore WC, et al. The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma. J Allergy Clin Immunol 2012;130:510-5.e1. https://doi.org/10.1016/j.jaci.2012.03.018
- Wan YI, Shrine NR, Soler Artigas M, Wain LV, Blakey JD, Moffatt MF, et al. Genome-wide association study to identify genetic determinants of severe asthma. Thorax 2012;67:762-8. https://doi.org/10.1136/thoraxjnl-2011-201262